CYP3A5 Polymorphism in Mexican Renal Transplant Recipients and its Association with Tacrolimus Dosing

Archives of Medical Research

Volumn 43, Issue 4, 2012, Pages 283-287

  García Roca, Pilar ^a   Medeiros, Mara ^a   Reyes, Herlinda ^a   Rodríguez Espino, Benjamín Antonio ^a   Alberú, Josefina ^b   Ortiz, Lourdes ^a   Vásquez Perdomo, Mayela ^a   Elizondo, Guillermo ^c   Morales Buenrostro, Luis Eduardo ^b   Mancilla Urrea, Eduardo ^d   Castañeda Hernández, Gilberto ^c  

^a HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

^d INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

CYP3A5; Interethnic variability; Mexican population; Pharmacogenetics; Renal transplant; Tacrolimus

Indexed keywords

CYTOCHROME P450 3A5; TACROLIMUS;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DNA SEQUENCE; DRUG BIOAVAILABILITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; GRAFT REJECTION; HETEROZYGOSITY; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY TRANSPLANTATION; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MALE; MEXICO; MULTICENTER STUDY; NEGRO; PHENOTYPE; STATISTICAL SIGNIFICANCE; WILD TYPE;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CHILD; CODON, NONSENSE; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP3A; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MEXICO; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN ISOFORMS; TACROLIMUS; YOUNG ADULT;

EID: 84864109520     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2012.05.005     Document Type: Article

References (33)

1. Marcen R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 2009, 69:2227-2243.
2. Millan O., Brunet M., Campistol J.M., et al. Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil. Clin Chem 2003, 49:1891-1899.
3. Park S.I., Felipe C.R., Pinheiro-Machado P.G., et al. Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus. Fundam Clin Pharmacol 2009, 23:137-145.
4. Mourad M., Wallemacq P., De Meyer M., et al. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome. Transplantation 2008, 85:S19-S24.
5. Lukas J.C., Calvo R., Zografidis A., et al. Simulation of sirolimus exposures and population variability immediately post renal transplantation: importance of the patient's CYP3A5 genotype in tailoring treatment. Biopharm Drug Dispos 2010, 31:129-137.
6. Mukonzo J.K., Waako P., Ogwal-Okeng J., et al. Genetic variations in ABCB1 and CYP3A5 as well as sex influence quinine disposition among Ugandans. Ther Drug Monit 2010, 32:346-352.
7. Xiang Q., Zhao X., Zhou Y., et al. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J Clin Pharmacol 2010, 50:659-666.
8. Park P.W., Seo Y.H., Ahn J.Y., et al. Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. J Clin Pharm Ther 2009, 34:569-574.
9. Yin O.Q., Tomlinson B., Chow M.S. CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition. J Clin Pharmacol 2010, 50:1136-1141.
10. Macphee I.A., Fredericks S., Tai T., et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002, 74:1486-1489.
11. MacPhee I.A., Fredericks S., Tai T., et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004, 4:914-919.
12. MacPhee I.A., Holt D.W. A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. Transplantation 2008, 85:163-165.
13. Staatz C.E., Tett S.E. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004, 43:623-653.
14. Thervet E., Anglicheau D., King B., et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003, 76:1233-1235.
15. Silva-Zolezzi I., Hidalgo-Miranda A., Estrada-Gil J., et al. Analysis of genomic diversity in Mexican Mestizo populations to develop genomic medicine in Mexico. Proc Natl Acad Sci USA 2009, 106:8611-8616.
16. Castaneda-Hernandez G., Hoyo-Vadillo C., Palma-Aguirre J.A., et al. Pharmacokinetics of oral nifedipine in different populations. J Clin Pharmacol 1993, 33:140-145.
17. Castaneda-Hernandez G., Palma-Aguirre J.A., Montoya-Cabrera M.A., et al. Interethnic variability in nifedipine disposition: reduced systemic plasma clearance in Mexican subjects. Br J Clin Pharmacol 1996, 41:433-434.
18. Chavez-Teyes L., Castaneda-Hernandez G., Flores-Murrieta F.J. Pharmacokinetics of midazolam in Mexicans: evidence for interethnic variability. Clin Drug Invest 1999, 17:233-239.
19. Palma-Aguirre J.A., Gonzalez-Llaven J., Flores-Murrieta F.J., et al. Bioavailability of oral cyclosporine in healthy Mexican volunteers: evidence for interethnic variability. J Clin Pharmacol 1997, 37:630-634.
20. Flores-Murrieta F.J., Castaneda-Hernandez G., Granados-Soto V., et al. Increased bioavailability of sildenafil in Mexican men. JAMA 2000, 283:1825-1826.
21. Gonzalez H.M., Romero E.M., Peregrina A.A., et al. CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans. J Clin Pharmacol 2003, 43:1211-1215.
22. Carrasco-Portugal M del C., Aguilar-Carrasco J.C., Lujan M., et al. Further evidence for interethnic differences in the oral pharmacokinetics of meloxicam. Clin Drug Investig 2005, 25:307-313.
23. Rozen S., Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000, 132:365-386.
24. Cueto-Manzano A.M., Morales-Buenrostro L.E., Gonzalez-Espinoza L., et al. Markers of inflammation before and after renal transplantation. Transplantation 2005, 80:47-51.
25. Medeiros-Domingo M., Romero-Navarro B., Valverde-Rosas S., et al. Renal transplantation in children. Rev Invest Clin 2005, 57:230-236.
26. Reyes-Hernandez O.D., Lares-Asseff I., Sosa-Macias M., et al. A comparative study of CYP3A4 polymorphisms in Mexican Amerindian and Mestizo populations. Pharmacology 2008, 81:97-103.
27. Dorado P., Sosa-Macias M.G., Penas-Lledo E.M., et al. CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards. Pharmacogenomics J 2010, 11:108-112.
28. Lopez M., Guerrero J., Jung-Cook H., et al. CYP2D6 genotype and phenotype determination in a Mexican Mestizo population. Eur J Clin Pharmacol 2005, 61:749-754.
29. Staatz C.E., Goodman L.K., Tett S.E. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: II. Clin Pharmacokinet 2010, 49:207-221.
30. Staatz C.E., Goodman L.K., Tett S.E. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: I. Clin Pharmacokinet 2010, 49:141-175.
31. Barry A., Levine M. A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients. Ther Drug Monit 2010, 32:708-714.
32. Tang H.L., Xie H.G., Yao Y., et al. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers. Pharmacogenet Genomics 2011, 21:713-720.
33. Coto E., Tavira B. Pharmacogenetics of calcineurin inhibitors in renal transplantation. Transplantation 2009, 88:S62-A67.